In June 2018, the GHPSJ received authorization from ARS (Agence Régionale de Santé) to establish a biomedical research site within the oncology department to conduct phase I clinical trials.
On July 2, 2018, our medical oncology department enrolled a very first patient in the study of sponsor Genoscience Pharma (N ° clinical trial: NCT03316222) for a first administration in humans of an innovative treatment.
This clinical trial concerns the GNS561 molecule, administered orally with a new mechanism of action for patients with liver cancer.
GNS561 mainly works by causing the death of cancer cells by their depletion of zinc, an essential element for the survival of cancers.
Find all information about this trial by clicking here.